Surface sanitizer with residual biocidal properties

Abstract

The invention relates to a surface disinfectant with residual biocidal properties. A disinfectant formulation is provided that imparts residual biocidal properties. The disinfectant formulation is used to treat a surface, after deposition of a film on the treated surface, to impart the film the ability to rapidly kill bacteria and other germs for at least 24 hours. The disinfectant formulation comprises a polymeric binder and a biocidal compound, wherein the polymeric binder is an oxazoline homopolymer or an extended or modified polymer based on an oxazoline homopolymer. The disinfectant formulation further comprises a carrier. Articles having the disinfectant formulations and methods of making, using, and applying the disinfectant formulations are provided.

Description

This application is a divisional application. The application date of the original application is November 24, 2015, the application number is 201580074480.9 (PCT / US2015 / 062471), and the name of the invention is "Surface disinfectant with residual biocidal properties".

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 084,917 filed in the U.S. Patent and Trademark Office on November 26, 2014, and U.S. Provisional Patent Application Serial No. 62 / 127,075 filed on March 2, 2015, and U.S. Provisional Patent Application Serial No. 62 / 166,403 filed on May 26, 2015, and U.S. Utility Patent Application Serial No. 14 / 948962 filed on November 23, 2015. The disclosures of which are incorporated herein by reference in their entireties. Field of the Invention

[0002] The present invention relates to the field of disinfectant formulations and, more particularly, to a disinfectant formulation imparting residual biocidal properties. Background of the Invention Microorganisms are present everywhere in the modern world. While some microorganisms are beneficial to humans and the environment, others can have significant negative consequences for contaminated products and for the humans, animals, and members of the ecosystem that come into contact with them. There are multiple industries and environments where such microorganisms are particularly prevalent.

[0003] Health Care Hospital-acquired infections (HAIs; or "nosocomial infections") are infections whose development is facilitated by a hospital or health care environment. Such illnesses are usually fungal or bacterial infections and can afflict the victim locally or systemically. Nosocomial infections can cause severe pneumonia as well as infections of the urinary tract, bloodstream, and other parts of the body.

[0004] Hospital infections have serious medical implications for patients and care providers. In the United States, data indicate that approximately 1,700,000 hospital-associated infections occur each year, with nearly 100,000 deaths resulting from infection. European data and surveys indicate that Gram-negative bacterial infections alone account for 8,000-10,000 deaths each year.

[0005] Several exacerbating factors contribute to high HAI rates. Hospitals, urgent care centers, nursing homes, and similar facilities focus their care on those with serious illnesses and injuries. As a result, these home facilities have an unusually high concentration of patient populations with weakened immune systems.

[0006] Three pathogens are commonly found in healthcare settings and together account for approximately one-third of nosocomial infections: coagulase-negative Staphylococci (15%), Candida species (11%), and Escherichia coli (10%).

[0007] Worse still, it is the more robust disease-causing pathogens that are present in such environments. Six so-called "ESKAPE pathogens" - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species - are antibiotic-resistant and are involved in nearly half of all hospital infections. Their resistance to one or more biocides makes such infections particularly dangerous.

[0008] In particular, the broad nutritional diversity of Pseudomonas allows it to survive in extreme environments, including on surfaces that are not adequately cleaned and sterilized. The ubiquity of this pathogen in hospital settings makes it a major cause of Gram-negative nosocomial infections. Particularly vulnerable are immunocompromised patients (e.g., those suffering from cystic fibrosis, cancer, or burns).

[0009] The most common means of HAIs is through direct or indirect contact transmission. Direct contact transmission involves a patient coming into contact with a contaminated patient or worker. As care providers move through health care facilities, they come into contact with many patients. As these workers care for residents, they unwittingly act in a manner similar to bees in gardens, "pollination" rooms, and wards.

[0010] Indirect contact transmission occurs when a patient comes into contact with a contaminated object or surface.The healthcare environment presents an array of articles capable of passively vectoring pathogens.

[0011] Nosocomial infections further contribute to the volume, quality and cost of health care provided by hospitals and other institutions that are severely underserved. In addition to the approximately 100,000 HAI-related deaths that occur in the United States each year, an estimated two million more victims are forced to endure the physical ravages and emotional distress associated with these serious and unavoidable illnesses.

[0012] The association has acted by creating policies to impose more stringent cleaning and disinfection requirements for staff and patient environments. These procedures typically include frequent hand washing and frequent surface disinfection. Despite the implementation of procedures to curb nosocomial infections, infections still occur at an unacceptably high rate.

[0013] Home Care and Household Domestic environments are also faced with microorganisms. The major drawback associated with consumer disinfectants and sanitizers is that, while they may be effective at killing microorganisms initially, surfaces are easily and quickly recontaminated by contact, airborne microorganisms, and residual microorganisms that were not killed before treatment. If simply left on the surface, although some disinfectants will continue to provide some control, this will result in a greasy or sticky residue that will easily fail by accidental contact with the surface. Therefore, it is desirable that home care and household cleaners kill microorganisms quickly upon contact and then be used as residual disinfectants, but do not yet have this undesirable sticky or sticky effect. Such cleaners can be used for general purpose household cleaning, bathroom cleaning, and spray protectants.

[0014] The difference between hospital and healthcare cleaners and household products is the allowable VOC (volatile organic content). The rule for most non-aerosol household consumer disinfectants is a maximum of 1% VOC.

[0015] Food Services The food service industry is also faced with contamination outbreaks of pathogens in the workplace and the spread of illness to consumers. Even if food manufacturers adopt vigorous sanitation programs and comply with strict government sanitation regulations, major microbial outbreaks are occasionally reported, which cause serious illness in consumers. Disinfectants with residual activity should effectively alleviate this problem.

[0016] In summary, there remains a need for formulations that can impart residual biocidal activity to treated surfaces. It would be further advantageous if the formulations were combined with surface disinfectants to enable a single clean to both disinfect and impart a residual biocidal effect.

[0017] It would be further advantageous if the residual biocidal properties could be durably associated with the treated surface so that they could continue to provide microbial reduction for an extended period of time after application.

[0018] It would be further advantageous if there were formulations that were effective across a wide range of industries and applications. SUMMARY OF THE INVENTION The present invention relates to a disinfectant formulation that imparts residual biocidal properties. The disinfectant formulation comprises a polymer binder and a biocidal compound, wherein the polymer binder is an oxazoline homopolymer or an extended or modified polymer based on an oxazoline homopolymer. The disinfectant formulation also comprises a carrier.

[0019] In one aspect of the invention, the oxazoline homopolymer has the following structure: wherein R1 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, glycosyl, halo, hydroxyl, oxazolinium methanesulfonate, oxazolinium toluenesulfonate, oxazolinium trifluoromethanesulfonate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group; and R2 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, glycosyl, halo, hydroxyl, oxazolinium methanesulfonate, oxazolinium toluenesulfonate, oxazolinium trifluoromethanesulfonate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group. R is a 1-4- 1,000,000 group or a macrocyclic structure; R is a 2- 1,000,000 group or a macrocyclic structure; R is a 1- 1,000,000 group or a macrocyclic structure; R is a 2- 1,000,000 group or a macrocyclic structure; R is a 1- 1,000,000 group or a macrocyclic structure; R is a 1- 1,000,000 group or a macrocyclic structure; R is a 1- 1,000,000 group or a macrocyclic structure; R is a 1- 1,000,000 group or a macrocyclic structure; R is a 1- 1,000,000 group or a macrocyclic structure; R is a 1- 1,000,000 group or a macrocyclic structure;

[0020] In another aspect of the invention, additional features of the disinfectant formulation are provided.

[0021] In yet another aspect of the present invention, articles having the disinfectant formulations of the present invention and methods of making, using and applying the disinfectant formulations are provided.

[0022] Further areas of applicability of the present invention will become apparent from the detailed description provided hereinafter.It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.

[0023] DESCRIPTION OF THE PREFERRED EMBODIMENTS The following description of the embodiments of the present invention is only exemplary and is in no way intended to limit the present invention, its application or use. The present invention has a wide range of potential applications and practicality and is expected to be applicable to a wide range of industries. By way of example only, the following description is provided herein for the purpose of providing the authorization disclosure of the present invention, but does not limit the scope or material of the present invention.

[0024] As used herein, the terms "microorganism" or "microbial" should be interpreted as referring to any microscopic organism studied by microbiologists or found in the environment in which the treated article is used. Such organisms include, but are not limited to, bacteria and fungi and other single-cell organisms such as molds, mildew and algae. Viral particles and other infectious agents are also included in the term microorganism.

[0025] "Antimicrobial" is also understood to include both bactericidal and antimicrobial properties. That is, the term encompasses microbial killing, resulting in a reduction in the number of microorganisms, as well as delayed effects of microbial growth, wherein the number may remain more or less unchanged (but still allowing for slight increases / decreases).

[0026] For ease of discussion, this description uses the term antimicrobial to indicate broad spectrum activity (e.g., against bacteria and fungi). When speaking of efficacy against specific microorganisms or taxonomic classes, more focused terms will be used (e.g., antifungal indicates efficacy against specific mold growth).

[0027] Using the above examples, it should be understood that efficacy against fungi in no way excludes the possibility that the same antimicrobial composition may demonstrate efficacy against another class of microorganisms.

[0028] For example, discussion of strong bacterial efficacy demonstrated by a disclosed embodiment should not be viewed as excluding that embodiment from also demonstrating antifungal activity. The methods presented should not be construed in any way as limiting the scope of the invention.

[0029] Disinfectant preparations The present invention relates to a disinfectant formulation. In one aspect of the present invention, the disinfectant formulation is in liquid form. The composition of the disinfectant formulation comprises a biocidal compound and a polymer binder. The composition may also comprise other components such as a solvent (such as water or a low molecular weight alcohol), a surfactant, a colorant, a fragrance, etc.

[0030] Liquid compositions are formulated to have surface disinfecting and residual biocidal properties. The formulations can be applied to surfaces by spraying, rolling, misting, wiping or other means. The formulations act as surface disinfectants, killing infectious microorganisms present on surfaces.

[0031] Once dry, the liquid formulation leaves a residual protective film on the surface. The residual film has biocidal properties, enabling it to maintain surface protection against microbial contamination for an extended period of time after its application.

[0032] In a preferred embodiment, the surface disinfectant formulation imparts to the film the ability to rapidly kill bacteria and other germs for at least 24 hours after the film is deposited on the treated surface. Rapid kill generally refers to a time period of about 30 seconds to about 5 minutes in one aspect of the invention. The film will remain on the surface and will last for multiple touches and surface abrasions.

[0033] The liquid composition comprises a polymeric binder, a biocidal compound, a carrier (such as a solvent) and other optional ingredients (such as fragrance).

[0034] Polymer Binders In one aspect of the present invention, the polymer binder is an oxazoline homopolymer. As another feature of the present invention, the oxazoline homopolymer has the following structure: in R1 and R2 are the end groups determined by the polymerization technique for synthesizing the oxazoline homopolymer.R1 and R2 are selected independently and include but are not limited to hydrogen, alkyl, alkenyl, alkoxyl, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxyalkyl, carboxyalkenyl, cyano group, glycosyl, halo, hydroxyl, oxazolinium methanesulfonate, oxazolinium toluenesulfonate, oxazolinium trifluoromethanesulfonate, silyl oxazolinium, phenol, polyalkoxy, quaternary ammonium, mercaptan or thioether group.Perhaps, R2 can comprise the macrocyclic structure formed during the building-up as a result of the intramolecular attack.

[0035] For example, in the cationically initiated polymerization of oxazoline, if methyl tosylate is used as the initiator, then R1 is methyl and R2 is oxazolinium tosylate.

[0036] R3 is the end group determined by the type of oxazoline for the preparation of polymer binder of the present invention.R3 includes but is not limited to hydrogen, alkyl, alkenyl, alkoxyl, aryl, benzyl, hydroxyalkyl or perfluoroalkyl.For example, if ethyl oxazoline is the monomer for the preparation of polymer binder of the present invention, then R3 is ethyl.

[0037] n is the degree of oxazoline polymerization in the homopolymer. n is in the range of 1-1,000,000. Preferably, n is in the range of 500-250,000; most preferably, n is in the range of 2500-100,000.

[0038] Similar to oxazoline homopolymer, the polymkeric substance of extension or modification with some variations based on oxazoline homopolymer is also applicable to the present invention.Be used to implement the technology and option that the chemistry or molecular structure of oxazoline are changed or modification should be familiar to those skilled in the art.Polymkeric substance of a class extension or modification based on oxazoline homopolymer can be represented by following molecular structure: in R1 and R3 have the same definitions as those given above for the oxazoline homopolymer.

[0039] B is other monomer repeating unit that is connected with oxazoline in multipolymer.The arrangement type of the repeating unit between B and the oxazoline in multipolymer can include but not limited to block, alternately, periodicity, or their combination.To the type that can be used for with oxazoline copolymerization of the present invention or modification B of oxazoline of the present invention is not restricted.

[0040] n is the degree of polymerization of the oxazoline repeating unit; in the copolymer, n is in the range of 1-1,000,000, and at the same time, in the copolymer, the degree of polymerization of the B repeating unit m is in the range of 0-500,000. Preferably, n is in the range of 500-250,000 and m is in the range of 20-10,000; most preferably, n is in the range of 2500-100,000 and m is in the range of 50-5,000. In addition to connecting B to ethyl oxazoline by copolymerization, if B itself is already a quaternary ammonium compound, by using B as a cationic initiator, in cationic polymerization, B can also be connected to oxazoline as an end group.

[0041] While not intended to be all-inclusive, B may be, for example, ethyleneimine having the following molecular structure: in The R1 and R2 end groups have the same definitions as those described for the oxazoline homopolymers.

[0042] R3 includes, but is not limited to, hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl.

[0043] R4 includes, but is not limited to, hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl.

[0044] m is in the range of 0-500,000; preferably, in the range of 20-10,000; most preferably, in the range of 50-5,000.

[0045] n is in the range of 1-1,000,000; preferably, 500-250,000; most preferably, in the range of 2500-100,000.

[0046] For example, the synthetic of oxazoline and ethyleneimine copolymer can be carried out in two steps in stages.In the first step, the cationic ring-opening polymerization technology can be used for the preparation of poly-oxazoline homopolymer.In the second step, the poly-oxazoline of preparation in the first step can be hydrolyzed, so that part poly-oxazoline repeating unit is converted into polyethyleneimine.Perhaps, oxazoline-ethyleneimine (ethylenimine) copolymer can use suitable corresponding monomer, oxazoline and aziridine preparation.The result will be the cationic polymer with above structure.

[0047] The degree of polymerization n of the oxazoline repeating unit in the copolymer is in the range of 1-1,000,000, and at the same time the degree of polymerization m of the ethyleneimine repeating unit in the copolymer is in the range of 0-500,000. Preferably, n is in the range of 500-250,000 and m is in the range of 20-10,000, most preferably n is in the range of 2500-100,000 and m is in the range of 50-5,000.

[0048] Alternatively, the nitrogen in the ethyleneimine repeat unit can be further quaternized to produce the following cationic copolymer: Any quaternization technique familiar to those skilled in the art can be used to quaternize the polymer of this example. R1, R2, R3 and R4 have the same meanings as those specified in the above oxazoline-ethyleneimine copolymer. R5 includes, but is not limited to, hydrogen, methyl, ethyl, propyl or other types of alkyl. The corresponding anion X - It is halogen, sulfonate, sulfate, phosphonate, phosphate, carbonate / bicarbonate, hydroxyl or carboxylate.

[0049] The ranges of n and m are also the same as those described in the oxazoline-ethyleneimine copolymer.

[0050] Another example of B that can be used in the present invention is polydiallyldimethylammonium chloride. The polyethyloxazoline modified by polydiallyldimethylammonium chloride has the following structure: in R1 and R4 have the same meanings as described in the previous examples for the quaternized oxazoline-ethyleneimine copolymer.

[0051] R2 and R3, independently, include but are not limited to short chain alkyl groups, such as C1-C6. The corresponding anion X - It is halogen, sulfonate, sulfate, phosphonate, phosphate, carbonate / bicarbonate, hydroxyl or carboxylate.

[0052] n and m are defined and have the same values ​​as in the previous example.

[0053] B can be other olefins, including but not limited to diallyldimethylammonium chloride, vinylbenzene, methoxylbenzene and methoxyethylene. Ethyl oxazoline can also be copolymerized with heterocyclic monomers, such as oxirane, thiocyclobutane, 1,3-dioxepane, oxetanes-2-one and tetrahydrofuran (THF), to enhance the performance of polymers of the present invention. Adhesives for the present invention can also adopt side oxazoline groups on polymer backbone, such as based on acrylic acid or vinylbenzene polymers or containing acrylic acid or vinylbenzene copolymers.

[0054] Examples of commercially available polyethyloxazolines include, but are not limited to, Aquazol 500 from Polymer Chemistry Innovations, Inc.

[0055] The amount of polymer binder that can be used in liquid preparations can vary slightly, depending on the desired length of residual activity of the composition and the properties of all other components in the composition. Preferably, the amount of polymer binder in the liquid preparation is in the range of 0.1%-20%, based on the weight of the liquid preparation. In liquid preparations for health care applications, the amount of polymer binder in the liquid preparation is more preferably in the range of 0.5%-10%, most preferably in the range of 0.8%-5%. In liquid preparations for general and bathroom cleaners, the amount of polymer binder in the liquid preparation is more preferably in the range of 0.1%-10%, most preferably in the range of 0.1%-5%.

[0056] The polymer binder is preferably water soluble and can be easily removed from the surface if any accumulation is noticed.Present in small amounts, it can still provide a durable bond between the biocidal compound and the treated surface to promote residual efficacy.

[0057] Biocidal compounds The biocidal compound may be a quaternary ammonium compound (QAC) having the following molecular structure: in R1, R2, R3 and R4 are independently selected and include, but are not limited to, alkyl, alkoxy or aryl, with or without heteroatoms, or saturated or unsaturated. Some or all of the functional groups may be the same.

[0058] The corresponding anion X - These include, but are not limited to, halogen, sulfonate, sulfate, phosphonate, phosphate, carbonate / bicarbonate, hydroxyl, or carboxylate.

[0059] QACs include, but are not limited to, n-alkyldimethylbenzyl ammonium chloride, di-n-octyldimethylammonium chloride, dodecyldimethylammonium chloride, n-alkyldimethylbenzylammonium saccharinate, and 3-(trimethoxysilyl)propyldimethyloctadecylammonium chloride.

[0060] Combinations of monomeric QACs are preferably used in the present invention. A specific example of a combination of QACs is N-alkyl dimethyl benzyl ammonium chloride (40%); N-octyl decyl dimethyl ammonium chloride (30%); di-n-decyl dimethyl ammonium chloride (15%); and di-n-dioctyl dimethyl ammonium chloride (15%). The percentages are weight percentages of the individual QACs, based on the total weight of the blended QAC composition.

[0061] Polymeric forms of QACs having the following structure may also be used in the present invention.

[0062] or in R1, R2, R5 and R6, independently, include but are not limited to hydrogen, methyl, ethyl, propyl or other longer carbon alkyl groups.

[0063] R3 and R4 are independently selected and include, but are not limited to, methylene, ethylene, propylene or other longer alkylene linking groups.

[0064] n is the degree of polymerization; n is an integer in the range of 2-10,000.

[0065] Examples of cationic polymers having the above structure include, but are not limited to, polyamines derived from dimethylamine and epichlorohydrin, such as Superfloc C-572 commercially available from Kemira Chemicals.

[0066] Yet another polymeric QAC suitable for use in the present invention is polydiallyldimethylammonium chloride or polyDADMAC.

[0067] Yet another class of QACs useful in the present invention are those chemical compounds having a biguanide moiety in the molecule. Examples of such cationic antimicrobials include, but are not limited to, PHMB and chlorhexidine.

[0068] Examples of commercially available quaternary ammonium compounds include, but are not limited to, Bardac 205M and 208M from Lonza, and BTC885 from Stepan Company.

[0069] The biocidal compound can be a weak acid, which has been shown to be particularly effective in bathroom cleaners. In these types of products, citric acid, aminosulfonic acid (also known as amidosulfonic acid, amidosulfuric acid, aminosulfonic acid, and aminosulfonic acid), glycolic acid, lactic acid, lauric acid, and capric acid can be used as both effective biocides and cleaners for soap scum and hard water deposits.

[0070] Other compounds that may be used are quaternary silane salts such as 3(trihydroxysilyl)propyldimethyloctadecyl ammonium chloride. These may have the added benefit of reacting with the surface being treated for enhanced residual properties.

[0071] Other biocidal compounds suitable for use in the liquid formulations of the present invention span a wide range of antimicrobials, biocides, disinfectants and sanitizers.Water soluble or dispersible biocidal compounds are preferred, although alcohol soluble biocides may alternatively be employed.

[0072] A non-exclusive list of biocidal compounds suitable for use in the formulations of the present invention includes triclosan, zinc pyrithione, metal salts and oxides, phenols, botanicals, halogens, peroxides, heterocyclic antimicrobials, aldehydes, and alcohols.

[0073] The concentration of the biocidal compound in the formulation may range from 0.05% to 20% based on the weight of the liquid composition. For liquid formulations for health care applications, it is preferably in the range of 0.1% to 20%, more preferably in the range of 0.5% to 3%. For liquid formulations for general and bathroom cleaners, it is preferably in the range of 0.05% to 10%. For formulations for protectants, it is preferably in the range of 0.05% to 2%.

[0074] Carrier The carrier or medium for the liquid preparation of the present invention can be any solvent with volatility and allows easy evaporation under ambient conditions. The example of liquid carrier includes but is not limited to water and low molecular weight alcohol, such as C1-C8 alkanol. Specific examples include but are not limited to ethanol, isopropanol, butanol, amyl alcohol, and their combination.

[0075] Another class of solvents for use in the present invention includes alkylene glycol ethers. Examples include, but are not limited to, ethylene glycol monopropyl ether, ethylene glycol monobutyl ether, ethylene glycol monohexyl ether, ethylene glycol monohexyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monohexyl ether, triethylene glycol monomethyl ether, triethylene glycol monoethyl ether, triethylene glycol monobutyl ether, propylene glycol methyl ether, propylene glycol methyl ether acetate, propylene glycol n-butyl ether, dipropylene glycol n-butyl ether, dipropylene glycol methyl ether, dipropylene glycol methyl ether acetate, propylene glycol n-propyl ether, dipropylene glycol n-propyl ether, and tripropylene glycol methyl ether.

[0076] Another class of solvents useful in the present invention is based on terpenes and their derivatives, such as terpene alcohols, terpene esters, terpene ethers or terpene aldehydes. Examples of solvents include, but are not limited to, pine oil, lemon oil, limonene, pinene, cymene, myrcene, fenchone, borneol, nopol, eucalyptol, ionone, and the like.

[0077] In liquid formulations for home care cleaning applications, the preferred carrier is water.

[0078] If the method of applying the liquid formulation of the present invention is a pressurized aerosol, a propellant may be required in the composition. A variety of propellants or mixtures can be used in the present invention and should be familiar to those skilled in the art. In aerosol compositions known in the industry, C1-C10 hydrocarbons or halogenated hydrocarbons are typical propellants. Examples of such propellants include, but are not limited to, pentane, butane, propane and methane. Other types of propellants that can be used in the present invention also include compressed air, nitrogen or carbon dioxide. Alternatively, a bag on a valve package can be used for an aerosol, without the need to directly add a propellant to the composition.

[0079] A single solvent or a mixture of the above solvents can be used in the present invention. The type of solvent used in the present invention may depend on the intended use of the residual disinfectant composition. For example, if the composition of the present invention is intended for home care use, cleaning contaminated surfaces free of all types of dust or dirt may be of primary concern. The liquid carrier or medium that assists and enhances the removal of dirt may be the formulation of the present invention. For example, the residual disinfectant formulation or composition of the present invention may desirably include an alkyl or polyalkyl glycol ether for better cleaning performance in the formulation of the present invention in a home care form. On the other hand, if the primary purpose of the residual disinfectant composition is for use in a health care facility where the primary concern is hospital-acquired infection, then rapid drying of the liquid composition of the present invention may be more desirable than cleaning dust or dirt from surfaces. Low molecular weight alcohols should be considered to assist the liquid formulation of the present invention in rapid drying after application. In addition, the low molecular weight alcohol in the liquid formulation will enhance the sterilizing activity of the liquid composition.

[0080] For health care uses of residual disinfectants, mixtures of water and low molecular weight alcohols are preferred. The amount of alcohol present in the liquid formulation is preferably at a level where the liquid formulation is capable of forming an azeotropic mixture between the alcohol and water. The minimum amount of alcohol (if present) in the liquid composition is 10%. Preferably, for health care uses of residual disinfectants, the alcohol concentration is 30%, and most preferably the alcohol concentration is at least 50%, based on the weight of the liquid formulation for health care uses of the composition of the present invention.

[0081] Surfactants Surfactants or wetting agents can be used. Surfactants help liquid preparations to spread and evenly coat the surface being treated. Surfactants additionally help to form azeotropic mixtures between alcohol and water, thus promoting rapid and uniform drying of liquid preparations once applied to the surface. If dirt cleaning performance is a key feature for a designed product, surfactants also play an important role in residual disinfectant liquid preparations of the present invention for home care purposes.

[0082] Surfactants suitable for use in the liquid formulations of the present invention include, but are not limited to, those that are nonionic, anionic, or amphoteric in nature. Examples of commercially available wetting agents include, but are not limited to, Ecosurf SA-4 or Tergitol TMN-3 from Dow Chemical and Q2-5211 from Dow Corning.

[0083] Amine oxide surfactants are particularly preferred when QACs are used as biocidal compounds in formulations.

[0084] In the category of nonionic surfactants, ethoxylated alcohols with varying amounts of ethylene oxide or HLB values ​​can be used. Examples of ethoxylated alcohols include, but are not limited to, Triton X-100 (Dow Chemical, Midland MI), the Ecosurf EH nonionic surfactant series from Dow Chemical, the Tergitol nonionic surfactant series from Dow Chemical, the Surfonic surfactant series from Huntsman Corp., the Neodol surfactant series from Shell, the Ethox surfactant series from Ethox Chemicals, and the Tomadol surfactant series from Air Products and Chemicals, Inc.

[0085] Another class of nonionic surfactants includes the alkyl polyglucosides. Examples include the Glucopon series from BASF and the Ecoteric series from Huntsman.

[0086] An alternative class of surfactants preferred for use in liquid formulations are silane-based surfactants. Examples include, but are not limited to, silicone polyethers, organofunctional or reactive silane wetting agents, and fluorochemical based wetting agents.

[0087] The content of the surfactant in the liquid preparation is in the range of 0%-10%, preferably in the range of 0.01%-5%.

[0088] Depending on the target use, the liquid formulation of the present invention for home care purposes may require appropriate pH conditions. For example, if the liquid product is used in the kitchen area, a high pH product may be desired to effectively remove the grease commonly found in this area. If the product is used in the bathroom area, soap scum and hard water deposits may be of major concern. In such a case, a low pH product may be more suitable for such a purpose. There is no restriction on the type of pH adjusting agent that can be added to the liquid composition of the present invention. Examples of usable pH adjusting agents include, but are not limited to, triethanolamine, diethanolamine, monoethanolamine, sodium hydroxide, sodium carbonate, potassium hydroxide, potassium carbonate, calcium carbonate, citric acid, acetic acid, hydrochloric acid, sulfamic acid, sulfuric acid, etc.

[0089] In addition to the above-mentioned components, additional functional components may be included in the liquid composition of the present invention. Additional components include, but are not limited to, chelating agents, compatibilizers, coupling agents, corrosion inhibitors, rheology modifiers, fragrances, colorants, preservatives, UV stabilizers, optical brighteners, and active ingredient indicators.

[0090] In one embodiment of the invention, liquid solution comprises polymer binder, quaternary ammonium compound, silicone-based surfactant and ethanol.Liquid preparation can be prepared or mixed by any conventional method known to those of ordinary skills.For preparation of the present invention, there is no preferred interpolation procedure, and condition is that preparation is finally homogeneous, compatible and stable.For example, if polymer binder is solid, can preferably at first dissolve or disperse polymer in carrier (such as water or alcohol), to prepare storage polymer binder liquid dispersion.During mixing procedure, storage polymer binder liquid dispersion can easily join in preparation of the present invention.

[0091] Administration of liquid preparations Liquid formulations can be applied by a variety of means. If sprayed, liquid formulations can advantageously be supplied in conventional bottles with a sprayer. The sprayer can be a trigger sprayer. As an option for a trigger sprayer, aerosols can also be used to deliver liquid formulations onto surfaces. Additional means of application include, but are not limited to, misting, rolling, brushing, mopping, and using wipes by a variety of application equipment. It is within the scope of the present invention that wipe products comprising or pretreated with the disinfectant formulations of the present invention can also be prepared, for example, for ready-to-use sale or use.

[0092] To disinfect contaminated surfaces, spray the liquid preparation until the area is completely covered. Wet preparations can then be wiped dry with a dry cloth or paper towel.

[0093] The present invention also relates to articles treated with the disinfectant formulations according to the various aspects of the present invention. Example

[0094] The following examples illustrate liquid formulations prepared according to various aspects of the present invention. Test results for these formulations demonstrate the desired residual sterilization or disinfection performance once applied to a surface and dried. Cleaning performance was also tested for those formulations that not only provided residual disinfection benefits but also provided cleaning characteristics.

[0095] The efficacy of the residual test preparation of EPA 01-1A scheme is used. Briefly, bacteria are added to a glass slide and allowed to dry on the surface. The preparation is then sprayed on the surface and dried to form a transparent film. Once a film has been formed, the glass slide is exposed to alternating wet and dry cycles using the Gardner abrasion tester as described in the scheme. Between each cycle, the glass slide is inoculated with bacteria again. After the appropriate amount of wear and re-inoculation (for health care preparations, 48 ​​passes and 11 re-inoculations, and for home care preparations, 24 passes and 5 re-inoculations), the glass slide is exposed to the time range of bacteria for indication (that is, 5 minutes), then recovered in a suitable neutralizing solution.

[0096] In addition to the residual efficacy, the compositions of the invention were also tested for initial efficacy according to ASTM E 1153.

[0097] A modified ASTM D4488 was used to evaluate the hard surface cleaning performance of the home care compositions of the present invention. Soils of the following composition were used for the evaluation.

[0098] Table 1 Components Weight percentage of each component (%) Pure vegetable oil 75 TM-122AATCC Carpet Soil 25 *TM-122 AATCC Carpet Soil from Textile Innovators In the process of preparing the soiled tiles for the cleaning test, about 2 g of liquid soil was placed on aluminum foil. The roller was used to roll and spread the soil on the foil, allowing the roller to pick up as much soil as possible. By rolling the soiled roller on the ceramic surface, the soil on the roller was evenly transferred to the glazed surface of the tile. The soiled tile was then baked in an oven set at 180°C for 45 minutes. The baked tile was conditioned at room temperature for 24 hours and then used in the cleaning test.

[0099] A Gardner abrasion tester was used in this cleaning test. A scouring pad of about 1 cm width was connected to an abrasion boat for abrasion. About 4 g of the test formulation was placed in a weighing boat. The connected scouring pad was immersed in the weighing boat to absorb the test formulation.

[0100] After the pad was wetted with the cleaning formulation, the cleaning process was started immediately. Seven wear cycles (backward and forward) were used for the test.

[0101] Examples of residual disinfectants used in healthcare The following formulations in the examples use alcohol as the primary carrier to provide fast drying properties to the liquid formulations.

[0102] Table 2 Components HE1 (weight %) HE2 (weight %) HE3 (weight %) water margin margin margin Ethanol 70 70 0 2-Propanol 0 0 70 Polyethyloxazoline 2 2 2 Quaternary ammonium compounds 0.8 1.2 1.2 Wetting agent / surfactant 0.1 0.1 0.1 Residual efficacy testing was performed using the EP01-1A regimen and the results are listed in the table below.

[0103] Table 3 preparation EP01-1A (average log reduction of bacteria) HE1 3.53 HE2 5.50 HE3 4.50 Based on the EP01-1A trial, these formulations showed excellent residual efficacy results.

[0104] The initial biocidal properties of HE2 were also evaluated using the ASTM E 1153 test protocol. The test results are presented in the table below.

[0105] Table 4 These data clearly demonstrate that sample surfaces treated with the exemplary liquid formulations disclosed herein have demonstrable biocidal activity over the indicated time frames.

[0106] Residual Disinfectant Cleaner Examples for Home Care These compositions are formulated using water as a carrier. They are intended for home care applications where VOC regulations prohibit the maximum use of high levels of organic solvents, such as alcohols.

[0107] Table 5 The residual efficacy of these formulations was assessed using the EP01-1A protocol and the results are listed in the table below.

[0108] Table 6 preparation EP01-1A (average log reduction of bacteria) H1 3.53 H2 5.50 H3 5.50 H4 4.90 H5 3.80 Enterobacter aerogenes was the bacterium used for the H1 test, while Staphylococcus aureus was the bacterium used for the remaining preparations.

[0109] The test results demonstrate that H1 to H5 all provide residual efficacy to the treated surfaces. Cleaning performance was also evaluated using a modified ASTM D4488 test method.

[0110] The test results also clearly show visually that the formulation of the present invention not only provides residual efficacy against bacteria, but also has good cleaning performance on soiled surfaces.

[0111] Additional formulations described in the following table were tested for home care and household cleaning applications. To solubilize fragrance, a premix containing fragrance, quaternary ammonium compound, surfactant and glycol ether (if present) was prepared.

[0112] Therefore, it is readily understood by those skilled in the art that the compositions and methods of the present invention are susceptible to a wide range of practicability and applications. Many embodiments and adaptations other than those described herein and many variations, modifications and equivalent arrangements will be apparent or reasonably suggested to those of ordinary skill in the art through this disclosure and the foregoing description thereof without departing from its substance or scope.

[0113] Therefore, while the compositions and methods of the present invention have been described in detail with respect to preferred embodiments thereof, it should be understood that this disclosure is illustrative and exemplary only and is intended only for the purpose of providing a full and enabling disclosure.

[0114] The foregoing disclosure is not intended or to be construed as limiting or otherwise excluding any such other embodiments, adaptations, variations, modifications and equivalent arrangements.

Claims

1. A disinfectant formulation imparting residual biocidal properties, the disinfectant formulation comprising: A polymer binder, wherein the polymer binder is an oxazoline homopolymer or an extended or modified polymer based on an oxazoline homopolymer and is present in the range of 0.1% to 5% by weight of the disinfectant formulation, and A biocidal compound, wherein the biocidal compound is a quaternary ammonium compound or a mixture of quaternary ammonium compounds and is present in the range of 0.1% to 2% based on the weight of the disinfectant formulation; wherein the quaternary ammonium compound is selected from the group consisting of n-alkyl dimethyl benzyl ammonium chloride, di-n-octyl dimethyl ammonium chloride, dodecyl dimethyl ammonium chloride, n-alkyl dimethyl benzyl ammonium saccharinate, 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride and combinations thereof.

2. The disinfectant formulation of claim 1, wherein the oxazoline homopolymer has the following structure: in R1 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, saccharyl, halo, hydroxy, oxazolinium methanesulfonate, oxazolinium tosylate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group; R2 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, glycosyl, halo, hydroxyl, oxazolinium methanesulfonate, oxazolinium toluenesulfonate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group or macrocyclic structure; R3 is hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl; and n is in the range of 1-1,000,000.

3. The disinfectant formulation of claim 1, wherein the extended or modified polymer based on the oxazoline homopolymer has the following structure: in R1 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, saccharyl, halo, hydroxy, oxazolinium methanesulfonate, oxazolinium tosylate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group; R3 is hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl; n is in the range of 1-1,000,000; B is a monomer repeating unit to which oxazoline is attached in the copolymer; and m ranges from 0-500,000.

4. The disinfectant formulation of claim 3, wherein B is ethyleneimine having the following structure: in R1 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, saccharyl, halo, hydroxy, oxazolinium methanesulfonate, oxazolinium tosylate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group; R2 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, glycosyl, halo, hydroxyl, oxazolinium methanesulfonate, oxazolinium toluenesulfonate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group or macrocyclic structure; R3 is hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl; R4 is hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl; m is in the range of 0-500,000; and n is in the range of 1-1,000,000.

5. The disinfectant formulation of claim 3, wherein B has the following structure: in R1 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, saccharyl, halo, hydroxy, oxazolinium methanesulfonate, oxazolinium tosylate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group; R2 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, glycosyl, halo, hydroxyl, oxazolinium methanesulfonate, oxazolinium toluenesulfonate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group or macrocyclic structure; R3 is hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl; R4 is hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl; R5 is hydrogen, methyl, ethyl, propyl or another type of alkyl group; m ranges from 0 to 500,000; n is in the range of 1-1,000,000; and X-, an anion, is a halogen, sulfonate, sulfate, phosphonate, phosphate, carbonate / bicarbonate, hydroxide or carboxylate.

6. The disinfectant formulation of claim 3, wherein B is a polyethyloxazoline modified with polydiallyldimethylammonium chloride having the following structure: in R1 is hydrogen, alkyl, alkenyl, alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl, carboxylalkyl, carboxylalkenyl, cyano, saccharyl, halo, hydroxy, oxazolinium methanesulfonate, oxazolinium tosylate, oxazolinium triflate, silyloxazolinium, phenol, polyalkoxy, quaternary ammonium, thiol or thioether group; R2 is a short chain alkyl group; R3 is a short chain alkyl group; R4 is hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl or perfluoroalkyl; m ranges from 0 to 500,000; n is in the range of 1-1,000,000; and X - , anion, is halogen, sulfonate, sulfate, phosphonate, phosphate, carbonate, bicarbonate, hydroxide or carboxylate.

7. The disinfectant formulation of claim 3, wherein B is an olefin selected from diallyldimethylammonium chloride, styrene, methoxystyrene, methoxyethylene, or another olefin.

8. The disinfectant formulation of claim 1, wherein the polymer binder is prepared using monomers of ethyloxazoline.

9. The disinfectant formulation of claim 8, wherein the ethyloxazoline is copolymerized with a heterocyclic monomer.

10. The disinfectant formulation of claim 1, wherein the polymeric binder employs pendant oxazoline groups on the polymer backbone.

Images